Literature DB >> 2862598

Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brain.

D G Kirch, M R Palmer, M Egan, R Freedman.   

Abstract

Haloperidol and its metabolite, reduced haloperidol, were compared as antagonists of catecholaminergic neurotransmission in central nervous system of the rat. Agonists and antagonists were applied from multibarrelled micropipettes, which were also used to record extracellularly the effects of these substances on neuronal discharge. Haloperidol antagonized dopaminergic inhibition of caudate neurons and inhibition of cerebellar Purkinje neurons induced by noradrenaline, whereas reduced haloperidol was an ineffective antagonist. Phencyclidine, which is an indirect dopaminergic agonist in the caudate, caused inhibition of the discharges of caudate neurons resembling that induced by dopamine itself. These indirect effects of phencyclidine were also antagonized by haloperidol but not by reduced haloperidol. The data suggest that the metabolite, reduced haloperidol, is not an effective neuroleptic drug in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862598     DOI: 10.1016/0028-3908(85)90021-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

1.  Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.

Authors:  M W Kelly; P J Perry; W H Coryell; D D Miller; S V Arndt
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 2.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Formation of active metabolites of psychotropic drugs. An updated review of their significance.

Authors:  S Caccia; S Garattini
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

4.  Interconversion between haloperidol and reduced haloperidol in healthy volunteers.

Authors:  B S Chakraborty; J W Hubbard; E M Hawes; G McKay; J K Cooper; T Gurnsey; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Authors:  S Ulrich; C Wurthmann; M Brosz; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

6.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs.

Authors:  W H Chang; S S Jaw; H S Wu; L Tsay; E K Yeh
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  The measurement of haloperidol and reduced haloperidol in hair as an index of dosage history.

Authors:  H Matsuno; T Uematsu; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

Review 9.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.